Your browser doesn't support javascript.
loading
The efficacy of Tadalafil 5mg in the treatment of lower urinary tract symptoms in patients where alpha blocker treatments have failed in terms of lower urinary tract symptoms. / Eficacia de Tadalafilo 5 mg en el tratamiento de los síntomas del tracto urinario inferior en pacientes tras fallo de los alfabloqueantes.
Atan, Ali; Polat, Fazli; Yesil, Süleyman; Ünsal, Ali; Bulut, Ender Cem; Tokuçoglu, Haluk; Dogan, Ahmet Emin.
Afiliação
  • Atan A; Department of Urology. Gazi University. School of Medicine. Ankara. Turkey.
  • Polat F; Department of Urology. Gazi University. School of Medicine. Ankara. Turkey.
  • Yesil S; Department of Urology. Gazi University. School of Medicine. Ankara. Turkey.
  • Ünsal A; Department of Urology. Gazi University. School of Medicine. Ankara. Turkey.
  • Bulut EC; Department of Urology. Gazi University. School of Medicine. Ankara. Turkey.
  • Tokuçoglu H; Department of Urology. Gazi University. School of Medicine. Ankara. Turkey.
  • Dogan AE; Department of Urology. Gazi University. School of Medicine. Ankara. Turkey.
Arch Esp Urol ; 72(7): 670-676, 2019 Sep.
Article em En, Es | MEDLINE | ID: mdl-31475678
ABSTRACT

OBJECTIVES:

To investigate the efficacy of tadalafil 5mg in patients with lower urinary tract symptoms who failed alpha blocker treatment. PATIENTS AND

METHODS:

Twenty-three patients were included. Patient consent was obtained after explaining the efficacy of tadalafil 5mg in lower urinary tract symptoms. Before initiating tadalafil 5mg treatment, prostate cancer and urinary tract infection in the patients were eliminated. IPSS, IIEF-5 and Qmax values were assessed before and one month after tadalafil 5mg treatment. Difference between two assessments was evaluated by the Wilcoxon method.

RESULTS:

After 1 month of Tadalafil 5mg treatment, IPSS decreased and IIEF-5 and Qmax increased. The difference between two assessments were statistically significant.

CONCLUSION:

Tadalafil 5mg once daily in the treatment of BPH/LUTS is found to be successful in patients who failed previous alpha blocker treatment.
RESUMEN

OBJETIVOS:

Investigar la eficacia de tadalafilo 5 mg en pacientes con síntomas del tracto urinario inferior (STUI) tras fallo de los alfabloqueantes. PACIENTES Y

MÉTODOS:

Treinta y tres pacientes fueron incluidos. Se obtuvo consentimiento informado en todos los casos tras explicarles la eficacia del tadalafilo 5 mg en el tratamiento de los STUI. Antes de iniciar el tratamiento se descartaron cáncer de próstata e infección urinaria. Se evaluaron los valores de los cuestionarios IPSS, IIEF-5 y el Q max antes del tratamiento y al mes del tratamiento. Las diferencias entre los grupos se evaluaron utilizando el método de Wilcoxon.   

RESULTADOS:

Después de un mes con tadalafilo 5 mg, el IPSS disminuyó, y el IIEF-5 y el Q max aumentaron. Las diferencias fueron estadísticamente significativas.

CONCLUSIONES:

Se ha visto que el tadalafilo 5 mg una vez al día es eficaz en el tratamiento de los STUI/HBP en pacientes con fallo previo del tratamiento con alfabloqueantes.
Assuntos
Palavras-chave
Buscar no Google
Base de dados: MEDLINE Assunto principal: Inibidores da Fosfodiesterase 5 / Sintomas do Trato Urinário Inferior / Tadalafila Idioma: En / Es Ano de publicação: 2019 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Inibidores da Fosfodiesterase 5 / Sintomas do Trato Urinário Inferior / Tadalafila Idioma: En / Es Ano de publicação: 2019 Tipo de documento: Article